Lim JW, et al. - Using optical coherence tomography, researchers compared the effects of highest-dose and lowest-dose pitavastatin therapy on coronary neointimal hyperplasia at 12-month follow-up in diabetic patients with non-ST-elevation acute coronary syndrome (NSTE-ACS). They randomized 72 diabetic patients with NSTE-ACS to lowest-dose pitavastatin (1 mg [n = 36]) or highest-dose pitavastatin (4 mg [n = 36]) after everolimus-eluting stent implantation. Administration of pitavastatin 4 mg led to significant improvement in inflammatory cytokines and lipid profiles compared to pitavastatin 1 mg during the 12-month follow-up, contributing to the reduction of neointimal hyperplasia and to the improvement of brachial artery flow-mediated dilation in these patients. This suggests the safety and efficacy of pitavastatin 4 mg use in high-risk patients requiring coronary stenting.